Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
PolyPid ( (PYPD) ) just unveiled an update.
PolyPid announced that its Phase 3 SHIELD II trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgeries, will continue enrollment to 800 patients following a positive recommendation from the Data Safety Monitoring Board. The company also secured a private placement financing of up to $41 million, which will extend its cash runway beyond potential NDA approval, allowing it to focus on completing the trial, preparing NDA and MAA submissions, and expediting partnership discussions.
More about PolyPid
PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which enables locally administered, controlled, prolonged-release therapeutics. Their primary product, D-PLEX100, is in a Phase 3 clinical trial aimed at preventing abdominal colorectal surgical site infections, with the company also exploring treatment options for solid tumors through its preclinical OncoPLEX program.
YTD Price Performance: -21.84%
Average Trading Volume: 19,103
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $20.21M
See more data about PYPD stock on TipRanks’ Stock Analysis page.
